FTC and seven states seek contempt finding against ‘Pharma Bro’ Shkreli over stock influence
The Federal Trade Commission and seven states say Martin Shkreli should be held in contempt for influencing biopharma stocks, according to MarketWatch.
MarketWatch·Oct 13, 2026, 3:37 PM·2 min read✓ Verified
Sources
Ask the Briefing · Pro
Ask follow-up questions answered from this story's reporting.
Unlock with Morning Briefing Pro